SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Looking forward, IMARC Group expects the 7MM to reach USD 4.6 Billion by 2035, exhibiting a growth rate (CAGR) of 10.55% during 2025-2035 ... for those living with this persistent skin disorder.

Let’s dive into the details with these 10 images. Revealed at the Bharat Mobility Global Expo 2025 (aka Auto Expo 2025), this ultra-premium electric MPV is the second addition to MG’s elite ...

The MG Majestor made its grand debut at Auto Expo 2025, as another entrant in the Indian SUV market. We break down the key design elements and expected features of the Majestor in our image gallery.

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

“It’s a matter of how, for whom, and at what price?” Read more from Jonathan. Peak U.S. sales of Humira, made by pharmaceutical giant AbbVie, were $18.6 billion in 2022. Then, in ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

The company is handling the erosion of Humira quite well ... but revenues were just $10 million above the low end of my $14.45-14.85 billion estimate range. However, that was still a good result ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...